Researchers make breakthrough in predicting the prognosis of triple-negative breast cancer

Scientists at Huntsman Cancer Institute at the University of Utah (the U), the National Cancer Institute-designated cancer center for the Mountain West, have made a significant breakthrough in predicting the prognosis of triple-negative breast cancer (TNBC), a particularly aggressive disease. Their research, published in JCO Precision Oncology as part of the TOWARDS study, has led to the development of a new mechanism that accurately forecasts the aggressiveness of TNBC. This advancement could revolutionize the way doctors treat TNBC, allowing them to identify higher-risk patients and tailor precise treatments.

Currently, TNBC lacks reliable methods to predict recurrence after treatments like chemotherapy and surgery. Unlike other breast cancers, TNBC is challenging to treat because its tumor cells lack estrogen receptors, progesterone receptors, and high levels of HER2/neu protein, according to experts at the National Institutes of Health. This often results in a higher likelihood of relapse after treatment.

Researchers used a patient-derived xenograft (PDX) model, where biopsies of tumors from patients were implanted into mice to grow human tumors. Alana Welm, PhD, senior author of the study, senior director of basic science at Huntsman Cancer Institute, and professor of oncological sciences at the U, highlights the significance of this method noting that it allows for an early and accurate assessment of the cancer's aggressiveness.

Cindy Matsen, MD, co-first author of the study, leader of the Breast and Gynecologic Disease Center at Huntsman Cancer Institute and associate professor in the Department of Surgery at the U, emphasizes the direct impact this research could have on patient care. She describes the study as highly relevant to addressing a major challenge in breast cancer treatment, with the potential of creating more personalized treatment plans for patients with recurrent TNBC.

The study's mechanism was more accurate than existing methods in predicting whether TNBC will recur. Welm notes, "By implanting a biopsy of the tumor into a PDX, we can discover how aggressive the cancer is. We hope to extend our new findings to improve the current standard tests used to predict whether the patients' cancer will recur."

This study addresses a very pressing problem in the clinic. PDX models help us not only predict with greater accuracy who will relapse and who will not, but also to treat recurrences with greater precision." 

Christos Vaklavas, MD, co-first author of the study, head of the breast cancer clinical program at Huntsman Cancer Institute, and associate professor of internal medicine at the School of Medicine at the University of Utah

Matsen also underscored the practical benefits of the study. In the second phase, now underway as a clinical trial, scientists are testing specific drugs on PDX models. If these therapies prove effective, results will be shared with physicians, providing them with valuable insights on how to guide treatment decisions.

The study's results are crucial: if a tumor grows in the PDX model, it often indicates a highly aggressive cancer, which is significantly harder to treat. Matsen stressed the urgency of improving treatment strategies, noting the devastating impact of the cancer recurrence.

"This study gives us the opportunity to provide hope and to save more lives," Matsen says.

Other Huntsman Cancer Institute scientists who contributed to the study include Kenneth Boucher, PhD, and Bryan Welm, PhD. This study was supported by the Department of Defense Breast Cancer Research Program, the National Institutes of Health/National Cancer Institute, including P30 CA02014, and Huntsman Cancer Foundation.

Source:
Journal reference:

Vaklavas, C., et al. (2024). TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer. JCO Precision Oncology. doi.org/10.1200/po.23.00724.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Liver cancer patients gain clarity on surgery options through precision medicine tool